RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Poster on Sortilin expression based on microarrayI think we can assume they will do as they have -- give us a decent business update which would include not just sales, new developments around projects, strategy/management, but also an update on what's going on with the trial. They have been following that pattern.
I would think we'll hear more "soft" stuff since it's not complete -- we can hope for a sense around enrollment, their view of how it's going, maybe a few anecdotes. But we'll get some kind of update.
For those "moaners", I would say use the web login and lob the specific question on the data you want to hear about and to whom's response you want and see if it gets picked. I've generally put in 3-4 questions on varying topics and plan to do the same. Turn your "moans" into solid "Queries" and you'll be happy. Maybe you get picked and it moves our understanding a step further toward de-risking an element of the thesis.
qwerty22 wrote: Anyway that's me moaning about other people moaning.
Let's hope the new IR person has a predictable MO. Last Q they put out the loan PR the day before the Q PR. Then they put out separate PRs for the clinical update and Q numbers the following day. Lets hope todays PR is the appetizer, I understand I'm raising expectations unnecessarily here.
qwerty22 wrote:
The negative reaction on this board to this PR. It's not the efficacy data, yes!
SPCEO1 wrote: I may not be readin what you said cirrectly but I am not sure what you were referring to when you said "It's really not understandable". Can you help me understand what is not understandable???
qwerty22 wrote: It's really not understandable. They aren't all expected to twiddle their thumbs and wait for the efficacy data to come in like we are, they have to get on with the other necessary stuff assuming the trial data will eventually come. They will (or won't) get past this efficacy moment and we'll be grateful they continued to work to put more meat on the bone in other areas
SPCEO1 wrote: I get the negative reaction to the press release today but I would draw everyone's attention to the "eagerly await the data readout" line of the PR. That is coded language indicating they have already seen good data in the phase 1b. Maybe they will share some of that tomorrow morning.
Theya re going on a roadshow with Truist next week - they need to make some news before that. And I doubt today's PR is that news. So, that suggests something more relevant will be shared tomorrow.
Biobob wrote: Just more can kicking.. tx selling and options coming up and guess what unless they pull an efficity rabbit we are going to the magical 1.50$ level... the no risk level of Th it seems... March / April here we come... take yours losses and buy it back no rush evryone.